Randomized Controlled Trial of PSMA PET/CT Guided Intensification of Radiotherapy for Prostate Cancer: Detection Rates and Impact on Radiotherapeutic Management

PSMA PET/CT is more sensitive in detecting prostate cancer than current imaging standard of care, and commonly influences patient management despite lack of evidence of impact on patient outcomes. Through the conduct of a Phase II randomized controlled trial (RCT - NCT03525288), we primarily sought to determine if intensification of radiotherapy based on PSMA PET/CT could lead to improved failure-free survival outcomes. Here, we report on our secondary endpoints in terms of rates of new lesion detection and radiotherapy (RT) intensification.